• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research